Physician profile
Mehandi Haran
NPI 1114103694
$3,206.42
in general payments reported to CMS, 2019-2025
27 companies · $999 in 2025
The $999 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $289 · 2021: $190 · 2022: $104 · 2023: $344 · 2024: $541 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,866 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,865.65 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,010.37 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals Lp | $369.50 | 2019-2025 | Fasenra, Tezspire |
| Genzyme Corporation | $315.70 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $207.85 | 2019-2025 | Uptravi |
| Sunovion Pharmaceuticals INC. | $201.18 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $189.20 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.25 | 2020-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Genentech USA, INC. | $125.21 | 2019-2020 | |
| Mylan Specialty L.P. | $97.87 | 2019-2022 | |
| Amgen INC. | $78.51 | 2024-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $62.76 | 2019-2025 | Winrevair, Zerbaxa |
| Grifols USA, LLC | $59.76 | 2025 | Prolastin-C Liquid |
| Insmed, INC. | $45.52 | 2021-2025 | Brinsupri, Arikayce |
| Pulmonx Corporation | $41.71 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Abiomed | $28.02 | 2022-2023 | Impella |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $27.17 | 2020 | |
| Gilead Sciences, INC. | $26.57 | 2019-2021 | |
| Verona Pharma, INC. | $23.43 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $19.40 | 2020 | |
| Cook Medical LLC | $17.12 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.92 | 2021 | |
| Pfizer INC. | $15.13 | 2019 | |
| United Therapeutics Corporation | $13.12 | 2020 | |
| Circassia INC. | $12.45 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.69 | 2020 | |
| La Jolla Pharmaceutical Company | $11.61 | 2019 | |
| Getinge USA Sales, LLC | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehandi Haran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.